Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would ...

Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and ...

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk said on Monday it will sell its blockbuster ...

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (NYSE:HIMS), an estimated $18.07 million trade based on quarterly average pricing.

Hims & Hers stock traded more than 40% higher after the deal was announced.

The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

Check out some of the companies making the biggest moves midday: Hims & Hers Health — Shares of the telehealth company jumped 3%. Bank of America upgraded the stock to neutral from underperform after ...

Shares of Hims surged as much as 50% in premarket trading, while Novo Nordisk’s Copenhagen-listed stock rose 1.7%. The ...